GENMAB AS SP.ADR/1/10DK 1 (GE91) — Capital Reinvestment Ratio
Latest as of December 2025:
0.04x
GENMAB AS SP.ADR/1/10DK 1 (GE91) has a Capital Reinvestment Ratio of 0.04x as of December 2025, meaning it reinvests 0% of its operating cash flow (€301.00 Million) in capital expenditures (€13.00 Million). See GE91 free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.04x
Capex / Operating Cash Flow
Operating Cash Flow
€301.00 Million
EUR
Capital Expenditures
€13.00 Million
EUR
Data as of
Dec 2025
Most recent filing
GENMAB AS SP.ADR/1/10DK 1 Capital Reinvestment Ratio (2021–2025)
This chart tracks GENMAB AS SP.ADR/1/10DK 1's Capital Reinvestment Ratio across 5 annual periods.
Annual Capital Reinvestment Ratio for GENMAB AS SP.ADR/1/10DK 1 (2021–2025)
Year-by-year Capital Reinvestment Ratio for GENMAB AS SP.ADR/1/10DK 1 from 2021 to 2025. For live market cap and broader valuation context, see market value of GENMAB AS SP.ADR/1/10DK 1.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.05x | €1.19 Billion | €55.00 Million | ▲ +18.5% |
| 2024 | 0.04x | €1.08 Billion | €42.41 Million | ▼ -23.2% |
| 2023 | 0.05x | €1.10 Billion | €55.83 Million | ▼ -37.1% |
| 2022 | 0.08x | €563.05 Million | €45.63 Million | ▼ -28.4% |
| 2021 | 0.11x | €339.18 Million | €38.36 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow